A detailed history of Rhumbline Advisers transactions in Genfit S.A. stock. As of the latest transaction made, Rhumbline Advisers holds 678 shares of GNFT stock, worth $2,488. This represents 0.0% of its overall portfolio holdings.

Number of Shares
678
Previous 678 -0.0%
Holding current value
$2,488
Previous $2,000 100.0%
% of portfolio
0.0%
Previous 0.0%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 08, 2024

SELL
$2.97 - $3.94 $371 - $492
-125 Reduced 15.57%
678 $2,000
Q2 2023

Aug 08, 2023

BUY
$3.54 - $4.68 $2,842 - $3,758
803 New
803 $2,000

Others Institutions Holding GNFT

About Genfit S.A.


  • Ticker GNFT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,815,500
  • Market Cap $183M
  • Description
  • Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagno...
More about GNFT
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.